IDEXX Laboratories, Inc. IDXX
Verdict: Strong sell. Fair value $388 against a price of $682 on 6 Jan 2026, 43% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: The OCF / Net Income ratio fell to 0.80 in 2022, indicating a temporary period where earnings....
Main risks
- High Beta (1.67) indicates significant stock price volatility relative to the broader market, posing a risk during market downturns.
- Potentially bearish options market sentiment, as suggested by a high Put/Call Open Interest Ratio of 2.35, which could signal investor concern or hedging activity.
- Incomplete financial data requires heavy reliance on proxies for critical metrics (e.g., EBIT, historical Invested Capital), which reduces the certainty of the analysis.
- Valuation prices in optimistic scenario (limited margin for error)
- Overhang: There are signals of caution emerging, including 'Possible Bearish Signals With IDEXX Labo...
- Market volatility